BOISE, Idaho--(BUSINESS WIRE)-- #BuiltOnRelationships--KB Home (NYSE: KBH), one of the largest and most trusted homebuilders in the U.S., today announced the grand opening of Pivot Pointe, a new community in desirable Meridian, Idaho. The new homes are designed for the way people live today, with popular features like modern kitchens overlooking large great rooms, bedroom suites with walk-in closets, and ample storage space. Pivot Pointe's two-story floor plans feature up to five bedrooms and three baths. Homeowners w.

PATRIOTISM MEETS HORSEPOWER: ANDY ROSS TO IGNITE BRISTOL DRAGWAY WITH ELECTRIFYING PERFORMANCE! NASHVILLE, TN, June 06, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), is excited to report that American Rebel CEO Andy Ross will perform at the Super Grip NHRA Thunder Valley Nationals Saturday, June 7, on the Midway Stage from 1:45 to 2:45 pm.

BETHESDA, Md.--(BUSINESS WIRE)--RLJ Lodging Trust (the “Company”) (NYSE: RLJ) today announced it will report financial results for the second quarter ended June 30, 2025, after the markets close on August 7, 2025. The Company will also host a conference call on August 8, 2025, at 10:00 a.m. (Eastern Time). The Company recommends that you dial in approximately 10 minutes before the call. The conference call can be accessed by dialing (877) 407-3982 or (201) 493-6780 for international participant.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that members of senior management will participate in the following upcoming investor conferences:

DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with …

Weyerhaeuser Company is the world's largest private owner of timberlands, generating revenues primarily from selling wood for homes. WY's main strengths are its scale, operational excellence, and exposure to rising wood demand for housing and exports. Pays a quarterly dividend currently yielding 3.2%, goes ex-dividend approximately 8/30.

Franklin Income Equity Focus ETF is a derivative income ETF with option strategies embedded in equity-linked notes. INCE has value characteristics and is well-balanced across sectors, with significant exposure in technology. INCE has reached its objective to provide lower volatility than the S&P 500.

DocuSign beat earnings and revenue estimates for Q1'26. The company remained highly FCF profitable and expanded its core subscription business. The market overreacted to lower billings, causing a 17% share price drop after-hours, which I see as a buying opportunity given the company's fundamentals. DocuSign generated solid free cash flow margins of 30% and raised its FY 2026 revenue outlook.

BEIJING , June 6, 2025 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced that it will release its financial results for the first quarter 2025 ended March 31, 2025, before the U.S. market opens on June 12, 2025. Uxin's management team will host a conference call on Thursday, June 12, 2025, at 8:00 A.M.

- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.

MONTREAL , June 6, 2025 /PRNewswire/ - (NYSE: CAE) (TSX: CAE) – CAE Inc. ("CAE") today announced that it has received regulatory approval to renew its normal course issuer bid ("NCIB") to purchase, for cancellation, up to 16,019,294 of its common shares commencing June 10, 2025 and ending June 9, 2026. The maximum number of common shares that may be repurchased under the program represents approximately five percent (5%) of the issued and outstanding common shares of CAE.

Nvidia Corp. (NASDAQ: NVDA) stock has bounced from a recent year-to-date low.

We're at the end of earnings season. That means it's time for analysts to weigh in on the outlook for specific stocks.

Dan Ives, Global Head of Tech at Wedbush, defends Tesla's long-term value despite Musk-Trump tensions. Sarah Kunst of Cleo Capital warns regulatory risks could hurt Tesla, SpaceX, and investor faith.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility.

Second Quarter Fiscal 2025 Summary (All comparisons are year-over-year unless otherwise noted) Revenue of $37.4 million, compared to $22.4 million, an increase of approximately 67% Gross loss of $(9.4) million compared to $(7.1) million, an increase of approximately 33% Loss from operations of $(35.8) million compared with $(41.4) million, a decrease of approximately 13% Net loss per share was $(1.79) compared with $(2.18), a decrease of approximately 18% Backlog of $1.26 billion, compared to $1.06 billion, an increase of approximately 19% Current Business Update Announcing restructuring plan to reduce operating expenses by 30% on an annualized basis compared to operating …

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of V.F. Corporation ("V.F.

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing …

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vestis Corporation ("Vestis Corporation") (NYSE:VSTS) concerning possible violations of federal securities laws. On May 6, 2025, Vestis reported a significant drop in 2Q 2025 revenue results that missed analysts' expectations.